Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$42.67 USD
+0.03 (0.07%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $42.71 +0.04 (0.09%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.67 USD
+0.03 (0.07%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $42.71 +0.04 (0.09%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) concluded the recent trading session at $52.49, signifying a -0.3% move from its prior day's close.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.28, indicating a -0.19% shift from the previous trading day.
Amgen (AMGN) Down 6.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead (GILD) & MRK's HIV Oral Combo Shows Efficacy in Phase II
by Zacks Equity Research
Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals with HIV.
Bristol Myers Squibb (BMY) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $50.89, indicating a +0.28% shift from the previous trading day.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.
New Strong Sell Stocks for February 26th
by Zacks Equity Research
BXMT, BMY and CWEN have been added to the Zacks Rank #5 (Strong Sell) List on February 26, 2023.
Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
by Zacks Equity Research
Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.
Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review
by Zacks Equity Research
Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.
Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
by Zacks Equity Research
Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
A Look at Pharma ETFs After Q4 Earnings
by Sweta Killa
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
New Strong Sell Stocks for February 12th
by Zacks Equity Research
ACLS, BMY and CHX have been added to the Zacks Rank #5 (Strong Sell) List on February 12, 2023.
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO
by Zacks Equity Research
Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO are included in this Analyst Blog.
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
by Zacks Equity Research
Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted
by Zacks Equity Research
Bristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo regimen to treat a lung cancer indication in the United States and EU.
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program
by Zacks Equity Research
JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC
by Zacks Equity Research
Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
Bristol-Myers (BMY) Q4 Earnings & Sales Beat, Stock Gains
by Zacks Equity Research
Bristol-Myers' (BMY) fourth-quarter 2023 earnings and sales surpass estimates as Reblozyl and Revlimid outperform. Shares rise on the same.
Nonfarm Payrolls Increased More Than Expected
by Zacks Equity Research
Nonfarm Payrolls Increased More Than Expected
BLS Jobs Up Big: 353K, 3.7% Unemployment
by Mark Vickery
353K new jobs created for January are nearly double the 180K or so analysts were looking for.
Compared to Estimates, Bristol Myers (BMY) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag
by Zacks Equity Research
Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.